NASDAQ:SRDX - SurModics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$49.15 +0.95 (+1.97 %)
(As of 05/23/2018 08:44 AM ET)
Previous Close$48.20
Today's Range$47.30 - $49.40
52-Week Range$22.65 - $49.45
Volume168,599 shs
Average Volume68,833 shs
Market Capitalization$639.03 million
P/E Ratio96.37
Dividend YieldN/A
Beta0.52

About SurModics (NASDAQ:SRDX)

SurModics logoSurmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio2.38
Quick Ratio2.26

Price-To-Earnings

Trailing P/E Ratio96.37
Forward P/E Ratio-2,457.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$73.11 million
Price / Sales8.91
Cash Flow$0.9793 per share
Price / Cash50.19
Book Value$8.55 per share
Price / Book5.75

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$3.92 million
Net Margins1.49%
Return on Equity5.33%
Return on Assets4.18%

Miscellaneous

Employees257
Outstanding Shares13,260,000

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) issued its earnings results on Wednesday, May, 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.01) by $0.08. The company had revenue of $19.06 million for the quarter, compared to analysts' expectations of $17.92 million. SurModics had a net margin of 1.49% and a return on equity of 5.33%. View SurModics' Earnings History.

What price target have analysts set for SRDX?

5 Wall Street analysts have issued 1-year price targets for SurModics' shares. Their predictions range from $43.00 to $76.00. On average, they anticipate SurModics' share price to reach $58.00 in the next twelve months. View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. According to Zacks Investment Research, "Surmodics exited the second quarter of fiscal 2018 on a solid note, beating the Zacks Consensus estimate on earnings and revenues. Further, solid performance in the In Vitro Diagnostics segment, which gained grounds on the back of strong growth and stabilization across BioFX, microarray and antigen product sales holds promise. Surmodics issued a solid guidance for fiscal 2018. On the flipside, the company witnessed significantly high operating losses. Product sales declined owing to shipment issues, particularly in the Medical Device segment. Further, foreign-exchange woes related to the Creagh Medical buyout have been a major dampener. Surmodics’ drug-coated balloons face stiff competition in niche space. The company’s margins are expected to be under pressure, due to expenses in the Irish facility infrastructure and lower Medical-Device product gross margins." (5/7/2018)
  • 2. Barrington Research analysts commented, "We are now modeling adjusted FY/18 adjusted EPS of $(0.02) and revenue of $78.4 million. DCB: Patient enrollment for the company’s TRANSCEND pivotal clinical trial continues and about half of U.S.-based clinical sites have now been activated. As a reminder, the trial to treat peripheral artery disease in the upper leg will be randomized and is expected to include 446 patients at up to 60 clinical sites in the U.S. and 18 sites in Europe. It will feature a head-to-head comparison with a competitor’s already commercialized drug-coated balloon product 510(k) products: Surmodics has now received FDA approvals for its first three 510(k) products (two balloon catheters and a microcatheter). Management remains hopeful that it will enter into partnership for all three products over the next two to four quarters Recommendation: We are maintaining our OUTPERFORM investment rating on SRDX shares. Our new price target is $43, up from our previous $38." (5/3/2018)
  • 3. Needham & Company LLC analysts commented, "SRDX is undergoing a transition from a supplier of medical device coatings to finished medical device products. In the near-term, this requires heavy R&D investment which has turned SRDX unprofitable. In the long-term, this should expand SRDX’s available market and accelerate its revenue growth. We believe that investors receive an inexpensive call option on SRDX’s DCBs at its current valuation. Given this, we are initiating coverage with a Buy rating." (2/27/2018)

Who are some of SurModics' key competitors?

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 55)
  • Mr. Andrew D. C. LaFrence CPA, VP of Fin. & Information Systems, CFO and Principal Accounting Officer (Age 55)
  • Mr. Bryan K. Phillips, Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec. (Age 47)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 54)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 52)

Has SurModics been receiving favorable news coverage?

Media coverage about SRDX stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SurModics earned a news impact score of 0.14 on Accern's scale. They also gave headlines about the company an impact score of 45.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are SurModics' major shareholders?

SurModics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.71%), Trigran Investments Inc. (10.40%), Northern Trust Corp (1.39%), Disciplined Growth Investors Inc. MN (1.34%), Millennium Management LLC (1.26%) and Allianz Asset Management GmbH (0.76%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Joseph J Stich and Susan E Knight. View Institutional Ownership Trends for SurModics.

Which major investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., State Board of Administration of Florida Retirement System, Citigroup Inc., Allianz Asset Management GmbH, Prudential Financial Inc., American International Group Inc. and BNP Paribas Arbitrage SA. Company insiders that have sold SurModics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj and Joseph J Stich. View Insider Buying and Selling for SurModics.

Which major investors are buying SurModics stock?

SRDX stock was acquired by a variety of institutional investors in the last quarter, including Trigran Investments Inc., BlackRock Inc., Algert Global LLC, Chicago Equity Partners LLC, Matarin Capital Management LLC, Barclays PLC, Northern Trust Corp and Spark Investment Management LLC. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $49.15.

How big of a company is SurModics?

SurModics has a market capitalization of $639.03 million and generates $73.11 million in revenue each year. The company earns $3.92 million in net income (profit) each year or $0.51 on an earnings per share basis. SurModics employs 257 workers across the globe.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for SurModics (SRDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SurModics (NASDAQ:SRDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for SurModics in the last 12 months. Their average twelve-month price target is $58.00, suggesting that the stock has a possible upside of 18.01%. The high price target for SRDX is $76.00 and the low price target for SRDX is $43.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $58.00$40.00$40.00$40.00
Price Target Upside: 18.01% upside6.38% upside45.19% upside45.19% upside

SurModics (NASDAQ:SRDX) Consensus Price Target History

Price Target History for SurModics (NASDAQ:SRDX)

SurModics (NASDAQ:SRDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Needham & Company LLCBoost Price TargetBuy$46.00 ➝ $55.00HighView Rating Details
5/3/2018Barrington ResearchBoost Price TargetOutperform$22.50 ➝ $43.00HighView Rating Details
5/2/2018Lake Street CapitalBoost Price TargetBuy$38.00 ➝ $76.00HighView Rating Details
3/1/2018SidotiUpgradeNeutral ➝ BuyLowView Rating Details
6/27/2017AegisInitiated CoverageBuyHighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

SurModics (NASDAQ:SRDX) Earnings History and Estimates Chart

Earnings by Quarter for SurModics (NASDAQ:SRDX)

SurModics (NASDAQ:SRDX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.12)
2019 EPS Consensus Estimate: ($0.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.01$0.01$0.01
Q2 20181$0.06$0.06$0.06
Q3 20181($0.08)($0.08)($0.08)
Q4 20181($0.11)($0.11)($0.11)
Q1 20191($0.01)($0.01)($0.01)
Q2 20191($0.01)($0.01)($0.01)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191($0.01)($0.01)($0.01)

SurModics (NASDAQ SRDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018Q2 2018($0.01)$0.07$17.92 million$19.06 millionViewN/AView Earnings Details
2/8/2018Q1 2018($0.05)$0.10$17.69 million$17.01 millionViewN/AView Earnings Details
11/8/2017Q4 2017($0.01)$0.18$16.98 million$20.06 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.01)$0.09$15.98 million$17.80 millionViewListenView Earnings Details
4/27/2017Q2 2017$0.07$0.05$16.21 million$17.50 millionViewN/AView Earnings Details
2/2/2017Q117$0.09$0.19$15.81 million$17.80 millionViewListenView Earnings Details
11/16/2016Q4 2016$0.09$0.26$16.09 million$18.20 millionViewListenView Earnings Details
7/28/2016Q316$0.12$0.37$16.31 million$19.97 millionViewListenView Earnings Details
5/2/2016Q2$0.09$0.20$14.71 million$16.70 millionViewListenView Earnings Details
1/28/2016Q116$0.17$0.38$14.58 million$16.50 millionViewListenView Earnings Details
11/10/2015Q415$0.19$0.30$15.30 million$17.40 millionViewListenView Earnings Details
8/5/2015Q315$0.21$0.26$14.86 million$15.90 millionViewListenView Earnings Details
4/30/2015Q2$0.20$0.19$14.09 million$14.40 millionViewListenView Earnings Details
1/29/2015Q414$0.21$0.25$14.30 million$14.20 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.26$14.90 million$15.30 millionViewN/AView Earnings Details
7/31/2014Q214$0.23$0.27$14.84 million$14.62 millionViewListenView Earnings Details
5/1/2014Q114$0.20$0.22$14.40 million$13.60 millionViewListenView Earnings Details
1/30/2014Q413$0.21$0.21$14.15 million$13.90 millionViewListenView Earnings Details
11/5/2013Q313$0.22$0.26$14.32 million$14.30 millionViewListenView Earnings Details
7/31/2013Q3 2013$0.21$0.22$15.03 million$14.29 millionViewListenView Earnings Details
5/7/2013Q2 2013$0.21$0.20$13.92 million$13.70 millionViewListenView Earnings Details
1/30/2013Q1 2013$0.18$0.29$13.63 million$13.85 millionViewListenView Earnings Details
11/6/2012Q412$0.17$0.17$13.83 million$13.80 millionViewN/AView Earnings Details
8/1/2012$0.14$0.17ViewN/AView Earnings Details
5/8/2012$0.15$0.14ViewN/AView Earnings Details
2/6/2012Q1 2012$0.11$0.11ViewN/AView Earnings Details
11/3/2011$0.05$0.06ViewN/AView Earnings Details
8/3/2011$0.04$0.13ViewN/AView Earnings Details
4/27/2011$0.08ViewN/AView Earnings Details
1/26/2011$0.05ViewN/AView Earnings Details
11/10/2010Q4 2010$0.13($0.05)ViewN/AView Earnings Details
7/28/2010Q3 2010$0.14$0.11ViewN/AView Earnings Details
4/28/2010Q2 2010$0.16$0.10ViewN/AView Earnings Details
1/27/2010Q1 2010$0.19$0.11ViewN/AView Earnings Details
11/4/2009Q4 2009$0.20$0.16ViewN/AView Earnings Details
7/29/2009Q3 2009$0.21$0.20ViewN/AView Earnings Details
4/29/2009Q2 2009$0.21$0.24ViewN/AView Earnings Details
1/28/2009Q1 2009$0.26$0.48ViewN/AView Earnings Details
11/5/2008Q4 2008$0.28$0.20ViewN/AView Earnings Details
7/23/2008Q3 2008$0.31$0.26ViewN/AView Earnings Details
4/23/2008Q2 2008$0.30$0.28ViewN/AView Earnings Details
1/23/2008Q1 2008$0.32$0.31ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

SurModics (NASDAQ:SRDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

SurModics (NASDAQ SRDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 83.70%
Insider Trading History for SurModics (NASDAQ:SRDX)
Insider Trading History for SurModics (NASDAQ:SRDX)

SurModics (NASDAQ SRDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Joseph J. StichVPSell1,000$33.53$33,530.00View SEC Filing  
12/11/2017Joseph J StichVPSell1,000$30.18$30,180.0046,450View SEC Filing  
9/15/2017Charles W OlsonVPSell801$27.85$22,307.8526,585View SEC Filing  
9/11/2017Joseph J. StichVPSell1,000$27.28$27,280.00View SEC Filing  
8/7/2017Gary R MaharajCEOSell5,000$25.75$128,750.00126,807View SEC Filing  
7/3/2017Gary R MaharajCEOSell5,000$28.03$140,150.00131,807View SEC Filing  
6/16/2017Bryan K PhillipsSVPSell1,226$24.85$30,466.1029,208View SEC Filing  
6/9/2017Joseph J StichVPSell1,000$25.31$25,310.0040,672View SEC Filing  
6/5/2017Gary R MaharajCEOSell2,702$25.09$67,793.18136,807View SEC Filing  
4/3/2017Gary R. MaharajCEOSell584$25.00$14,600.00View SEC Filing  
3/6/2017Joseph J. StichVPSell1,000$24.73$24,730.00View SEC Filing  
12/22/2016Charles W OlsonVPSell1,201$26.00$31,226.0027,386View SEC Filing  
12/8/2016Charles W OlsonVPSell3,699$26.02$96,247.9828,587View SEC Filing  
12/5/2016Joseph J StichVPSell1,000$23.97$23,970.0042,362View SEC Filing  
12/2/2016Bryan K PhillipsSVPSell1,264$23.90$30,209.6029,170View SEC Filing  
11/25/2016Charles W OlsonVPSell500$26.02$13,010.0027,245View SEC Filing  
11/7/2016Gary R MaharajCEOSell5,000$25.22$126,100.00130,207View SEC Filing  
10/3/2016Gary R. MaharajCEOSell5,000$29.55$147,750.00View SEC Filing  
8/17/2016Charles W OlsonVPSell9,936$28.98$287,945.2833,098View SEC Filing  
8/15/2016Susan E. KnightDirectorSell1,548$28.64$44,334.72View SEC Filing  
8/1/2016Charles W OlsonVPSell12,500$27.08$338,500.0035,531View SEC Filing  
6/14/2016Bryan K PhillipsSVPSell1,816$23.44$42,567.0425,350View SEC Filing  
6/10/2016Joseph J StichVPSell1,000$23.33$23,330.0023,492View SEC Filing  
5/27/2016Susan E KnightDirectorSell1,001$22.71$22,732.7116,470View SEC Filing  
3/4/2016Timothy J ArensVPSell10,291$18.43$189,663.139,196View SEC Filing  
12/4/2015Joseph J StichVPSell1,000$21.18$21,180.0021,464View SEC Filing  
9/4/2015Joseph J StichVPSell1,000$23.57$23,570.0022,464View SEC Filing  
6/5/2015Joseph J StichVPSell1,000$23.84$23,840.00View SEC Filing  
5/22/2015Bryan K PhillipsSVPSell7,293$25.25$184,148.25View SEC Filing  
12/29/2014Charles W OlsonVPSell5,083$21.98$111,724.34View SEC Filing  
12/8/2014Charles W OlsonVPSell3,365$21.66$72,885.90View SEC Filing  
11/19/2014Timothy J ArensVPSell10,330$21.02$217,136.60View SEC Filing  
5/8/2014Susan KnightDirectorBuy1,500$20.36$30,540.004,800View SEC Filing  
12/4/2013Bryan PhillipsSVPSell16,236$22.95$372,616.2016,233View SEC Filing  
5/15/2013Mark A LehmanInsiderSell1,693$26.55$44,949.15View SEC Filing  
8/10/2012Value Lp StarboardMajor ShareholderSell257,560$17.74$4,569,114.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SurModics (NASDAQ SRDX) News Headlines

Source:
DateHeadline
Surmodics finance chief to depart May 25Surmodics finance chief to depart May 25
seekingalpha.com - May 17 at 10:18 AM
Surmodics Announces Leadership Change and Appointment of Interim CFOSurmodics Announces Leadership Change and Appointment of Interim CFO
finance.yahoo.com - May 17 at 10:17 AM
Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial OfficerBiothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer
finance.yahoo.com - May 17 at 10:17 AM
BRIEF-Surmodics Acquires Thrombectomy Technology AssetsBRIEF-Surmodics Acquires Thrombectomy Technology Assets
www.reuters.com - May 16 at 4:01 PM
Needham & Company LLC Raises SurModics (SRDX) Price Target to $55.00Needham & Company LLC Raises SurModics (SRDX) Price Target to $55.00
www.americanbankingnews.com - May 16 at 1:49 PM
Surmodics (SRDX) Hits a 52-Week High, Can the Run Continue?Surmodics (SRDX) Hits a 52-Week High, Can the Run Continue?
finance.yahoo.com - May 15 at 10:40 AM
SurModics, Inc. (SRDX) Receives Consensus Recommendation of "Buy" from AnalystsSurModics, Inc. (SRDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 13 at 7:39 PM
SurModics (SRDX) Rating Increased to Strong-Buy at BidaskClubSurModics (SRDX) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 9 at 8:52 AM
SurModics (SRDX) Upgraded by Zacks Investment Research to "Buy"SurModics (SRDX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 7 at 2:31 PM
Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises ViewSurmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View
www.zacks.com - May 7 at 9:48 AM
Q3 2018 Earnings Estimate for SurModics, Inc. (SRDX) Issued By Barrington ResearchQ3 2018 Earnings Estimate for SurModics, Inc. (SRDX) Issued By Barrington Research
www.americanbankingnews.com - May 7 at 3:04 AM
Comparing SurModics (SRDX) & Baxter International (BAX)Comparing SurModics (SRDX) & Baxter International (BAX)
www.americanbankingnews.com - May 5 at 11:23 AM
SurModics (SRDX) Price Target Raised to $43.00SurModics (SRDX) Price Target Raised to $43.00
www.americanbankingnews.com - May 3 at 11:15 PM
SurModics (SRDX) Issues Quarterly  Earnings ResultsSurModics (SRDX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 3 at 2:34 PM
Edited Transcript of SRDX earnings conference call or presentation 2-May-18 12:30pm GMTEdited Transcript of SRDX earnings conference call or presentation 2-May-18 12:30pm GMT
finance.yahoo.com - May 3 at 9:50 AM
SurModics (SRDX) Given New $76.00 Price Target at Lake Street CapitalSurModics (SRDX) Given New $76.00 Price Target at Lake Street Capital
www.americanbankingnews.com - May 2 at 6:30 PM
SurModics (SRDX) Stock Rating Upgraded by ValuEngineSurModics (SRDX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM
CORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 GuidanceCORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
www.businesswire.com - May 2 at 4:04 PM
Surmodics (SRDX) CEO Gary Maharaj on Q2 2018 Results - Earnings Call TranscriptSurmodics' (SRDX) CEO Gary Maharaj on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 4:04 PM
Surmodics Increases 2018 Guidance - Quick FactsSurmodics Increases 2018 Guidance - Quick Facts
www.nasdaq.com - May 2 at 9:53 AM
Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 GuidanceSurmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
finance.yahoo.com - May 2 at 9:53 AM
SurModics: Fiscal 2Q Earnings SnapshotSurModics: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - May 2 at 9:53 AM
Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark ...Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark ...
www.nasdaq.com - May 1 at 4:00 PM
FDA clears Surmodic low-profile catheterFDA clears Surmodic' low-profile catheter
seekingalpha.com - April 23 at 4:01 PM
BRIEF-Surmodics Announces FDA Clearance Of A New .018” Low-Profile Pta Balloon Dilation CatheterBRIEF-Surmodics Announces FDA Clearance Of A New .018” Low-Profile Pta Balloon Dilation Catheter
www.reuters.com - April 23 at 9:43 AM
BidaskClub Lowers SurModics (SRDX) to HoldBidaskClub Lowers SurModics (SRDX) to Hold
www.americanbankingnews.com - April 16 at 12:19 AM
SurModics (SRDX) Downgraded by ValuEngine to "Sell"SurModics (SRDX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 14 at 8:01 PM
Edited Transcript of SRDX presentation 27-Mar-18 6:30pm GMTEdited Transcript of SRDX presentation 27-Mar-18 6:30pm GMT
finance.yahoo.com - April 12 at 11:00 AM
SurModics (SRDX) Downgraded to "Hold" at Zacks Investment ResearchSurModics (SRDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 2:53 PM
SRDX or HAE: Which is a Better Medical Product Stock?SRDX or HAE: Which is a Better Medical Product Stock?
www.zacks.com - April 9 at 10:18 AM
Heres Why You Should Invest in Surmodics (SRDX) Right NowHere's Why You Should Invest in Surmodics (SRDX) Right Now
finance.yahoo.com - April 4 at 5:35 PM
Here's Why You Should Invest in Surmodics (SRDX) Right NowHere's Why You Should Invest in Surmodics (SRDX) Right Now
finance.yahoo.com - April 4 at 5:35 PM
SurModics (SRDX) Upgraded to "Buy" by ValuEngineSurModics (SRDX) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 3 at 12:00 AM
Can The Uptrend Continue for Surmodics (SRDX)?Can The Uptrend Continue for Surmodics (SRDX)?
finance.yahoo.com - April 1 at 10:11 AM
SurModics (SRDX) Receives Buy Rating from Needham & Company LLCSurModics (SRDX) Receives Buy Rating from Needham & Company LLC
www.americanbankingnews.com - March 27 at 5:44 PM
SurModics (SRDX) Lifted to "Buy" at BidaskClubSurModics (SRDX) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
SurModics (SRDX) Upgraded to "Hold" by BidaskClubSurModics (SRDX) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 25 at 1:58 PM
SurModics, Inc. (SRDX) Receives Consensus Rating of "Buy" from AnalystsSurModics, Inc. (SRDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 7:33 PM
Head-To-Head Contrast: SurModics (SRDX) versus Cardiovascular Systems (CSII)Head-To-Head Contrast: SurModics (SRDX) versus Cardiovascular Systems (CSII)
www.americanbankingnews.com - March 23 at 1:16 AM
Surmodics to Present at Upcoming Investor ConferencesSurmodics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 15 at 9:59 AM
SurModics, Inc. (SRDX) VP Sells $33,530.00 in StockSurModics, Inc. (SRDX) VP Sells $33,530.00 in Stock
www.americanbankingnews.com - March 13 at 8:51 PM
SurModics (SRDX) vs. Exactech (EXAC) Critical ComparisonSurModics (SRDX) vs. Exactech (EXAC) Critical Comparison
www.americanbankingnews.com - March 12 at 3:08 PM
Landauer (LDR) and SurModics (SRDX) Head-To-Head ReviewLandauer (LDR) and SurModics (SRDX) Head-To-Head Review
www.americanbankingnews.com - March 4 at 7:08 PM
BidaskClub Upgrades SurModics (SRDX) to "Hold"BidaskClub Upgrades SurModics (SRDX) to "Hold"
www.americanbankingnews.com - March 3 at 10:02 PM
SurModics (SRDX) & Inogen (INGN) Financial ContrastSurModics (SRDX) & Inogen (INGN) Financial Contrast
www.americanbankingnews.com - March 1 at 3:08 PM
SurModics (SRDX) Upgraded by Sidoti to BuySurModics (SRDX) Upgraded by Sidoti to Buy
www.americanbankingnews.com - March 1 at 12:30 PM
Abbott to Strengthen Vascular Care Arm With Surmodics DealAbbott to Strengthen Vascular Care Arm With Surmodics Deal
www.zacks.com - March 1 at 9:43 AM
SurModics (SRDX) Upgraded at Barrington ResearchSurModics (SRDX) Upgraded at Barrington Research
www.americanbankingnews.com - February 28 at 7:58 PM
SurModics (SRDX) Price Target Raised to $38.00 at Lake Street CapitalSurModics (SRDX) Price Target Raised to $38.00 at Lake Street Capital
www.americanbankingnews.com - February 28 at 4:44 PM
SurModics (SRDX) Research Coverage Started at Needham & Company LLCSurModics (SRDX) Research Coverage Started at Needham & Company LLC
www.americanbankingnews.com - February 27 at 10:48 PM

SEC Filings

SurModics (NASDAQ:SRDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SurModics (NASDAQ:SRDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SurModics (NASDAQ SRDX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.